Advaxis (ADXS) Reports Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
Tweet Send to a Friend
Advaxis, Inc. (NASDAQ: ADXS) today announced updated median overall survival data from its Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
